In the second half of 2021 the number of deals relating to precision and personalized medicine decreased significantly by 54.1% from the same period in 2020.

This marks an acceleration in growth from the 86.7% decrease in deals that occurred in H1 2021 relative to the same period a year earlier.

GlobalData’s deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.

During second half of 2021, deals relating to precision and personalized medicine accounted for 6.3% of all deals taking place in the sector. This represents a decrease from the figure of 10.8% in second half of 2020.

GlobalData's thematic approach to sector activity seeks to group key company information on investments to see which industries are best placed to deal with any issues they may encounter.

These themes, of which precision and personalized medicine is one, are best thought of as "any issue that keeps a CEO awake at night", and by tracking them, it becomes possible to ascertain which companies are leading the way on specific issues and which ones have some work to do.